NOTICIAS
Gaithersburg, Maryland and SEOUL, Korea, March 2, 2015 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that Health Canada has approved its 6-target Allplex™ Respiratory Panel 5 assay, which identify Influenza virus A and B, RSV A and B, and Influenza A virus subtypes H1 and H3. Allplex™ tests are based on Seegene’s innovative MuDT™ technology enabling simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis... Ver más
South Korean molecular diagnostics company Seegene Inc. has won a 10 billion won ($9 million) worth contract to supply diagnostic kits for sexually transmitted infections (STIs) and human papilloma virus (HPV) to state-run hospitals in Italy for five years after beating 12 other strong contestants, the company announced on Monday... Ver más
EVENTOS
Abril 6, 2016
Auditorio del InDRE
Assays based on MuDTTM (Multiple Detection Temperatures) PCR Technology for In-Vitro Diagnostic
III JORNADAS DE INFLAMACIÓN, UNA VISIÓN TRASLACIONAL
Noviembre 6 - 8, 2017
Auditorio 5
Unidad de Congresos
Dr. Ignacio Morones Prieto
CMN SXXI, IMSS
XLVII CONGRESO NACIONAL MEXICANO DE PATOLOGÍA CLÍNICA
Noviembre 1 - 4, 2017
Centro Expositor
Ciudad de Puebla
© 2017 Ampli Bio S.A. de C.V.
Ampli Bio SA de CV
Av. San Jerónimo 1172, Col. San Jerónimo Lídice
Del. La Magdalena Contreras, Ciudad de México, C.P. 10200
Tels: 53771601, 53771617
Información dirigida exclusivamente a profesionales de la salud